STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology
company dedicated to developing, commercializing and marketing
innovative products for the treatment of dermatologic conditions,
today announced it will host a virtual key opinion leader (KOL)
event on XTRAC® and TheraClear®X on Wednesday, September 20, 2023,
at 10:00 AM – 12:00 PM ET. To register for the event, click here.
The event will feature presentations from the following
experts:
- Ashish Bhatia, MD, FAAD, Director of
Dermatologic, Laser & Cosmetic Surgery at Oak Dermatology,
Associate Professor of Clinical Dermatology at Northwestern
University, Feinberg School of Medicine
- Joel Cohen, MD, FAAD, FACMS, Director of
AboutSkin Dermatology and DermSurgery, and AboutSkin Research
- Iltefat Hamzavi, MD, FAAD, Physician at
Hamzavi Dermatology Specialists and Senior Staff Physician, Henry
Ford Health System Department of Dermatology
- Michael Nazareth, MD, PhD, FAAD, President of
Western New York Dermatology
This event will discuss STRATA’s dermatological devices, XTRAC®
and TheraClear®X, their mechanism of action, how STRATA’s devices
fit into the current treatment landscape, and how practices are
effectively integrating the devices into their service offerings.
STRATA’s CEO, Bob Moccia, will also provide a business update
addressing the company’s current and future growth plans.
A live question and answer session will follow the formal
presentations. A replay will be available after the call on the
company’s investor relations webpage.
About Ashish Bhatia, MD,
FAADDr. Ashish Bhatia is a board-certified and
fellowship-trained dermatologist and dermatologic surgeon. He is an
internationally recognized expert in dermatologic surgery and
cosmetic surgery with expertise in facial and body aesthetic
surgery, skin cancer therapy, Mohs and reconstructive surgery,
laser surgery, and skin resurfacing procedures, including scar
reduction and revision. Dr. Bhatia has contributed to the
advancement of techniques in facial reconstruction, scar revision,
fat reduction, and the use of purified neurotoxins and fillers. He
has published extensively in journals and textbooks and is a
sought-after teacher, speaker, and instructor both nationally and
internationally. He has helped bring over 25 drugs and devices to
market, including the development of 2 acne devices.
Dr. Bhatia received his medical degree from Northeastern Ohio
University College of Medicine where he was inducted into the Alpha
Omega Alpha national medical honors society and earned awards for
both achievement and service. He completed his residency in
dermatology at the Medical College of Virginia Hospitals where he
served as chief resident. Subsequently, he completed an intensive
fellowship in Mohs surgery, cutaneous oncology, reconstruction,
cosmetic, and laser surgery at SkinCare Physicians in Boston, MA
under the direction of leaders in the field from Boston University,
Harvard University, and Yale University School of Medicine. Dr.
Bhatia is an associate professor of clinical dermatology at
Northwestern University, Feinberg School of Medicine. He previously
served as chairman of the department of dermatology at DuPage
Medical Group. Dr. Bhatia’s memberships include the American
Academy of Dermatology, the American Society for Dermatologic
Surgery, the American Society for Laser Medicine and Surgery, the
American College of Mohs Surgery, and the American Medical
Association.
About Joel Cohen, MD, FAAD,
FACMSJoel L. Cohen, MD (FAAD, FACMS) is an
internationally-recognized expert on aesthetics and skin cancer. He
is the Director of AboutSkin Dermatology and DermSurgery, and
AboutSkin Research in metropolitan-Denver, Colorado. He was named a
Top Dermatologist by US News and World Report, Castle Connelly Top
Doctor (2013-2023), and voted by his peers as one of Denver's Top
Doctors in 5280 magazine 10-times. He is a Board-Certified
Dermatologist, and Fellowship-trained in Mohs Surgery, Lasers and
Cosmetic Dermatology.
Dr. Cohen has published over 294 medical articles and book
chapters, and has co-authored 3 academic textbooks. He lectures
every month at national meetings as well as at many international
congresses, and has participated in over 100 clinical trials
including key aesthetic lasers and devices. He is on the teaching
faculty of the University of California Irvine as an Associate
Professor of Dermatology. Dr. Cohen has received many prestigious
awards including the Melanoma Research Foundation Humanitarian of
the Year Award, the ASDS Public Service Award, the ASDS Patient
Safety Hero Award, the ASDS Excellence in Education Award, the
ASCDAS Distinguished Service Award, and the ASDS Traveling
Mentorship & Teaching Award.
He has been quoted in many newspapers & magazines including:
Vogue, TIME, Glamour, Elle, Allure, The New York Times (x4),
Reader’s Digest, Shape, USA Today, US News & World Report,
InStyle, BuzzFeed, MSN.com, ABC.com, NewBeauty, Condé Nast, Men’s
Health, Huffington Post, International Business Times, Consumer
Reports (x8), SELF, Women’s Health and MORE Magazine.
He regularly appears on Denver TV stations (with over 75
appearances discussing aesthetic issues, dermatology, and skin
cancer), and has been a guest on many segments of SiriusXM Doctor
Radio. He was also featured on the Emmy Award winning show “The
Doctors.”
About Iltefat Hamzavi, MD,
FAADDr. Iltefat Hamzavi, M.D., has practiced at Hamzavi
Dermatology Specialist offices since 2001 and sees general
dermatology with a special focus on pigmentary disorders and
hidradenitis suppurativa. He earned his Bachelor of Arts degree,
with honors, in Sociology from the University of Michigan, Ann
Arbor. Dr. Hamzavi received his medical degree from the University
of Michigan Medical School and graduated with academic honors in a
variety of specialty rotations. He completed his residency in
dermatology at Wayne State University and then spent time in Europe
training at some of the world’s leading skin care centers. In 2001,
he completed an advanced one-year laser and photo-medicine
fellowship at the University of British Columbia in Vancouver. Dr.
Hamzavi is an active clinic researcher and investigates causes and
treatments for vitiligo, hidradenitis suppurativa, photomedicine,
and other conditions. He also serves as senior staff physician at
Henry Ford Health System Department of Dermatology, and teaches
medical students at Wayne State University. He has co-authored over
300 peer reviewed papers which have been cited over 12000 times in
highly respected journals. He also volunteers his time with a
variety of non-profits in education, civic engagement and bringing
attention to debilitating skin diseases, and has served as founding
Co-Chair of the Global Vitiligo Foundation, board member at the
Photodermatology society and as President of the Hidradenitis
Suppurativa Foundation.
About Michael Nazareth, MD, PhD,
FAADMichael Nazareth is the president of Western New York
Dermatology and a board certified dermatologist. He was born and
raised in Buffalo and attended St. Joe’s Collegiate Institute for
High School. He earned a BS in biology at Canisius College and then
went on to the State University of New York at Buffalo School of
Medicine and Biomedical Sciences, where he earned his MD and PhD
degrees. He then completed a dermatology residency at SUNY Buffalo,
during which time he trained at Roswell Park Cancer Institute,
Women and Children’s Hospital of Buffalo, Buffalo General Medical
Center and the Veterans Administration Hospital. He was chief
resident in the final year of his residency training. Dr. Nazareth
is a member of the American Academy of Dermatology, the Society for
Pediatric Dermatology, the American Society for Dermatologic
Surgery, the American Medical Association and the Medical Society
of the State of New York. Dr. Nazareth looks forward to working
closely with patients of all ages to meet their complete
dermatologic needs by offering a comprehensive range of medical,
surgical, and cosmetic treatments.
About XTRAC®The XTRAC excimer
laser is an in-office based device that allows dermatology
professionals to precisely deliver targeted UVB light therapy to
specific treatment areas of the skin, for both adult and pediatric
patients suffering from inflammatory skin conditions such as
vitiligo, psoriasis, and atopic dermatitis.
About
TheraClear®XTheraClearX
is engineered and indicated specifically for the treatment of acne.
By combining vacuum technology and intense broadband light
(500nm-1200nm), TheraClearX shows significant promise in the fight
against acne. For best results, it is recommended patients complete
4-6 treatment sessions (scheduled 1-2 weeks apart), dependent on
acne severity. Treatments can be completed in 15-20 minutes and are
pain-free.
About STRATA Skin Sciences, Inc.STRATA Skin
Sciences is a medical technology company dedicated to developing,
commercializing and marketing innovative products for the in-office
treatment of various dermatologic conditions such as psoriasis,
vitiligo, and acne. Its products include the XTRAC® excimer laser,
VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting technologies in the U.S.
through its unique Partnership Program. STRATA’s popular
partnership approach includes a fee per treatment cost structure
versus an equipment purchase, installation and use of the device,
on-site training for practice personnel, service and maintenance of
the equipment, dedicated account and customer service associates,
and co-op advertising support to help raise awareness and promote
the program within the practice.
Safe HarborThis press release includes
"forward-looking statements" within the meaning of the Securities
Litigation Reform Act of 1995. These statements include but are not
limited to the Company’s plans, objectives, expectations and
intentions and may contain words such as “will,” “may,” “seeks,”
and “expects,” that suggest future events or trends. These
statements, the Company’s ability to launch and sell an acne
treatment device and to integrate that device into its product
offerings, the Company’s ability to develop, launch and sell
products recently acquired or to be developed in the future, the
Company’s ability to develop social media marketing campaigns,
direct to dermatologist marketing campaigns, and the Company’s
ability to build a leading franchise in dermatology and aesthetics,
are based on the Company’s current expectations and are inherently
subject to significant uncertainties and changes in circumstances.
Actual results may differ materially from the Company’s
expectations due to financial, economic, business, competitive,
market, regulatory, adverse market conditions labor supply
shortages, or supply chain interruptions resulting from the
coronavirus, fiscal, and political factors, responses, or
conditions affecting the Company, the medical device industry and
our customers and patients in general, as well as more specific
risks and uncertainties set forth in the Company’s SEC reports on
Forms 10-Q and 10-K. Given such uncertainties, any or all these
forward-looking statements may prove to be incorrect or unreliable.
The statements in this press release are made as of the date of
this press release, even if subsequently made available by the
Company on its website or otherwise. The Company does not undertake
any obligation to update or revise these statements to reflect
events or circumstances occurring after the date of this press
release. The Company urges investors to carefully review its SEC
disclosures available at www.sec.gov and
www.strataskinsciences.com.
Investor Contact:Rich CockrellCG CapitalPhone:
+1 (404) 736-3838sskn@cg.capital
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2024 to May 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From May 2023 to May 2024